Immunogenicity and protective efficacy of mannosylated liposomes containing inactivated human malaria parasites — ASN Events
  1. Schedule
  2. Poster Session Three
  3. Immunogenicity and protective efficacy of mannosylated liposomes containing inactivated human malaria parasites

Immunogenicity and protective efficacy of mannosylated liposomes containing inactivated human malaria parasites (#377)

Aloysious Ssemaganda 1 , Ashwini K Giddam 1 , Leanne M Low 1 , Mei-fong Ho 1 , Xue Q Liu 1 , Mariusz Skwarczynski 2 , Istvan Toth 2 3 4 , Danielle I Stanisic 1 , Michael F Good 1
  1. Institute for Glycomics , Griffith University, Gold Coast, QUEENSLAND, Australia
  2. School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland, Australia
  3. School of Pharmacy , The University of Queensland, Brisbane, Queensland, Australia
  4. Institute for Molecular Bioscience, The University of , Brisbane, Queensland, Australia

In the search for a safe and effective malaria vaccine, the need for potent adjuvants and antigen delivery systems remains paramount. Liposomes have been previously shown to promote antigen presentation and augment delivery of vaccine antigens for subsequent processing.

In this study, the utility of mannosylated liposomes containing killed human malaria parasites was investigated in a mouse model.  BALB/c mice received 3 subcutaneous immunizations of liposomes containing an equivalence of 106 or 107 purified P. falciparum (7G8 strain) trophozoites and subsequently challenged with P. yoelii 17x mouse strain.

Cell mediated immune responses to both P. falciparum and Py17x as well as 7G8 specific antibody responses were observed following immunization. Additionally, immunized mice were strongly protected from a heterologous Py17x infection. Efforts are underway to investigate the mechanisms of immune protection.

Mannosylated liposomes thus present a novel vaccine adjuvant and antigen delivery system that maybe further exploited for the development of a vaccine against malaria.  Furthermore, the ability of liposomes containing P. falciparum to protect mice against P. yoelii presents an opportunity to accelerate transition to human trials.

#ASI2017QLD